Download Free Medical A Primary Care Approach To Ckd Management PowerPoint Presentation

A Primary Care Approach To Ckd Management PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "A Primary Care Approach to CKD Management”.

This medical PowerPoint presentation is about chronic kidney disease (CKD), a common and often asymptomatic condition that can lead to significant morbidity and mortality if not managed appropriately. As a primary care provider, you play a critical role in the management of CKD.

This presentation provides some key principles to guide your approach to CKD management.

Tags : CKD Management, chronic kidney disease, Nephrology, Nephrology PowerPoint presentation

Published on : Jun 07, 2023 | Views : 636 | Downloads : 1

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

A Primary Care Approach to CKD Management
Slide 2-

Learning Objectives Facilitate timely testing and intervention in patients at-risk for chronic kidney disease (CKD). Apply appropriate clinical measures to manage risk and increase patient safety in CKD. Co-manage and refer patients to nephrology specialists, when appropriate, in order to improve outcomes in CKD.
Slide 3-

A 50-year-old Hispanic female was diagnosed with type 2 diabetes at age 30. She has taken medications as prescribed since diagnosis. The fact that she has confirmed diabetes puts this patient at: A. Higher risk for kidney failure and CVD B. Higher risk for kidney failure only C. Higher risk for CVD only D. None of the above Case Question 1
Slide 4-

A 42-year-old African American man with diabetic nephropathy and hypertension has a stable eGFR of 25 mL/min/1.73m2. Observational Studies of Early as compared to Late Nephrology Referral have demonstrated which of the following? A. Reduced 1-year Mortality B. Increase in Mean Hospital Days C. No change in serum albumin at the initiation of dialysis or kidney transplantation D. Decrease in hematocrit at the initiation of dialysis or kidney transplantation E. Delayed referral for kidney transplantation Case Question 2
Slide 5-

Primary Care Providers – First Line of Defense Against CKD Primary care professionals can play a significant role in early diagnosis, treatment, and patient education A greater emphasis on detecting CKD, and managing it prior to referral, can improve patient outcomes CKD is Part of Primary Care
Slide 6-

The Public Burden of CKD
Slide 7-

CKD as a Public Health Issue 26 million American affected Prevalence is 11-13% of adult population in the US 28% of Medicare budget in 2013, up from 6.9% in 1993 $42 billion in 2013 Increases risk for all-cause mortality, CV mortality, kidney failure (ESRD), and other adverse outcomes. 6 fold increase in mortality rate with DM + CKD Disproportionately affects African Americans and Hispanics NKF Fact Sheets. http://www.kidney.org/news/newsroom/factsheets/FastFacts. Accessed Nov 5, 2014. USRDS. www.usrds.org. Accessed Nov 5, 2014. Coresh et al. JAMA. 2007. 298:2038-2047. ESRD, end stage renal disease
Slide 8-

CKD-CVD-Diabetes Link: CKD is a Disease Multiplier
Slide 9-

Overall expenditures for CKD in the Medicare population age 65 & older Point prevalent Medicare CKD patients age 65 & older; costs are total expenditures per calendar year. USRDS ADR, 2013
Slide 10-

Per person per month (PPPM) expenditures during the transition to ESRD, by dataset, 2011 Incident Medicare (age 67 & older) & Truven Health MarketScan (younger than 65) ESRD patients, initiating in 2008. USRDS ADR, 2013 Preventing progression of CKD will help hold down costs as the treatment of kidney failure is expensive. ESRD requires some type of replacement therapy to maintain life.
Slide 11-

CKD Risk Factors* Modifiable Diabetes Hypertension History of AKI Frequent NSAID use Non-Modifiable Family history of kidney disease, diabetes, or hypertension Age 60 or older (GFR declines normally with age) Race/U.S. ethnic minority status *Partial list AKI, acute kidney injury
Slide 12-

ESRD, end stage renal disease USRDS ADR, 2007 Diabetes and hypertension are leading causes of kidney failure Incident ESRD rates, by primary diagnosis, adjusted for age, gender, & race.
Slide 13-

CKD Screening and Evaluation
Slide 14-

Gaps in CKD Diagnosis Szczech, Lynda A, et al. "Primary Care Detection of Chronic Kidney Disease in Adults with Type-2 Diabetes: The ADD-CKD Study (Awareness, Detection and Drug Therapy in Type-2 Diabetes and Chronic Kidney Disease)." PLOS One - In press (2014).
Slide 15-

Improved Diagnosis… Studies demonstrate that clinician behavior changes when CKD diagnosis improves. Significant improvements realized in:1-3 Increased urinary albumin testing Increased appropriate use of ACEi or ARB Avoidance of NSAIDs prescribing among patients with low eGFR Appropriate nephrology consultation Wei L, et al. Kidney Int. 2013;84:174-178. Chan M, et al. Am J Med. 2007:120;1063-1070. Fink J, et al. Am J Kidney Dis. 2009,53:681-668.
Slide 16-

Screening Tools: eGFR Considered the best overall index of kidney function. Normal GFR varies according to age, sex, and body size, and declines with age. The NKF recommends using the CKD-EPI Creatinine Equation (2009) to estimate GFR. Other useful calculators related to kidney disease include MDRD and Cockroft Gault. GFR calculators are available online at www.kidney.org/GFR. Summary of the MDRD Study and CKD-EPI Estimating Equations: https://www.kidney.org/sites/default/files/docs/mdrd-study-and-ckd-epi-gfr-estimating-equations-summary-ta.pdf
Slide 17-

Screening Tools: ACR Urinary albumin-to-creatinine ratio (ACR) is calculated by dividing albumin concentration in milligrams by creatinine concentration in grams. Creatinine assists in adjusting albumin levels for varying urine concentrations, which allows for more accurate results versus albumin alone. Spot urine albumin-to-creatinine ratio for quantification of proteinuria New guidelines classify albuminuria as mild, moderately or severely increased First morning void preferable 24hr urine test rarely necessary
Slide 18-

Criteria for CKD Abnormalities of kidney structure or function, present for >3 months, with implications for health Either of the following must be present for >3 months: ACR >30 mg/g Markers of kidney damage (one or more*) GFR <60 mL/min/1.73 m2 *Markers of kidney damage can include nephrotic syndrome, nephritic syndrome, tubular syndromes, urinary tract symptoms, asymptomatic urinalysis abnormalities, asymptomatic radiologic abnormalities, hypertension due to kidney disease.m²
Slide 19-

Old Classification of CKD as Defined by Kidney Disease Outcomes Quality Initiative (KDOQI) Modified and Endorsed by KDIGO Note: GFR is given in mL/min/1.732 m² National Kidney Foundation. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis 2002;39(suppl 1):S1-S266 KDIGO, Kidney Disease: Increasing Global Outcomes
Slide 20-

Classification of CKD Based on GFR and Albuminuria Categories: “Heat Map” Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppls. 2013;3:1-150.
Slide 21-

CKD Management and the PCP
Slide 22-

Goals of Care in CKD Slow decline in kidney function Blood pressure control1 ACR <30 mg/g: ≤140/90 mm Hg ACR 30-300 mg/g: ≤130/80 mm Hg* ACR >300 mg/g: ≤130/80 mm Hg Individualize targets and agents according to age, coexistent CVD, and other comorbidities ACE or ARB *Reasonable to select a goal of 140/90 mm Hg, especially for moderate albuminuria (ACR 30-300 mg/g.)2 Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. Kidney Int Suppl. (2012);2:341-342. KDOQI Commentary on KDIGO Blood Pressure Guidelines. Am J Kidney Dis. 2013;62:201-213.
Slide 23-

Slowing CKD Progression: ACEi or ARB Risk/benefit should be carefully assessed in the elderly and medically fragile Check labs after initiation If less than 25% SCr increase, continue and monitor If more than 25% SCr increase, stop ACEi and evaluate for RAS Continue until contraindication arises, no absolute eGFR cutoff Better proteinuria suppression with low Na diet and diuretics Avoid volume depletion Avoid ACEi and ARB in combination1,2 Risk of adverse events (impaired kidney function, hyperkalemia) Kunz R, et al. Ann Intern Med. 2008;148:30-48. Mann J, et al. ONTARGET study. Lancet. 2008;372:547-553.
Slide 24-

Goals of Care in CKD: Glucose Control Target HbA1c ~7.0% Can be extended above 7.0% with comorbidities or limited life expectancy, and risk of hypoglycemia Risk of hypoglycemia increases as kidney function becomes impaired Declining kidney function may necessitate changes to diabetes medications and renally-cleared drugs NKF KDOQI. Diabetes and CKD: 2012 Update.Am J Kidney Dis. 2012 60:850-856.
Slide 25-

Modification of Other CVD Risk Factors in CKD Smoking cessation Exercise Weight reduction to optimal targets Lipid lowering therapy In adults >50 yrs, statin when eGFR ≥ 60 ml/min/1.73m2; statin or statin/ezetimibe combination when eGFR < 60 ml/min/1.73m2 In adults < 50 yrs, statin if history of known CAD, MI, DM, stroke Aspirin is indicated for secondary but not primary prevention Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppls. 2013;3:1-150.
Slide 26-

Detect and Manage CKD Complications Anemia Initiate iron therapy if TSAT ≤ 30% and ferritin ≤ 500 ng/mL (IV iron for dialysis, Oral for non-dialysis CKD) Individualize erythropoiesis stimulating agent (ESA) therapy: Start ESA if Hb <10 g/dl, and maintain Hb <11.5 g/dl. Ensure adequate Fe stores. Appropriate iron supplementation is needed for ESA to be effective CKD-Mineral and Bone Disorder (CKD-MBD) Treat with D3 as indicated to achieve normal serum levels 2000 IU po qd is cheaper and better absorbed than 50,000 IU monthly dose. Limit phosphorus in diet (CKD stage 4/5), with emphasis on decreasing packaged products - Refer to renal RD May need phosphate binders
Slide 27-

Detect and Manage CKD Complications Metabolic acidosis Usually occurs later in CKD Serum bicarb >22mEq/L Correction of metabolic acidosis may slow CKD progression and improve patients functional status1,2 Hyperkalemia Reduce dietary potassium Stop NSAIDs, COX-2 inhibitors, potassium sparing diuretics (aldactone) Stop or reduce beta blockers, ACEi/ARBs Avoid salt substitutes that contain potassium Mahajan, et al. Kidney Int. 2010;78:303-309. de Brito-Ashurst I, et al. J Am Soc Nephrol. 2009;20:2075-2084.
Slide 28-

A Balanced Approach to Nutrition in CKD: Macronutrient Composition and Mineral Content* Adapted from DASH (dietary approaches to stop hypertension) diet.*Adjust so total calories from protein, fat, and carbohydrate are 100%. Emphasize such whole-food sources as fresh vegetables, whole grains, nuts, legumes, low-fat or nonfat dairy products, canola oil, olive oil, cold-water fish, and poultry. NKF KDOQI. Am J Kidney Dis. 2007;49(suppl 2):S1-S179. *(CKD Stages 1-4)
Slide 29-

What can primary care providers do? Recognize and test at-risk patients Educate patients about CKD and treatment Manage blood pressure and diabetes Address other CVD risk factors Monitor eGFR and ACR (encourage labs to report these tests)
Slide 30-

What can primary care providers do? Evaluate and manage anemia, malnutrition, CKD-MBD, and other complications in at-risk patients Refer to dietitian for nutritional guidance Consider patient safety issues in CKD Consult or team with a nephrologist (co-management) Refer patient to nephrology when appropriate
Slide 31-

Co-Management, Patient Safety, and Nephrology Specialist Referral
Slide 32-

Co-Management Model Collaborative care Formal arrangement Curbside consult Care coordination Clinical decision support Population health Development of treatment protocols
Slide 33-

Collaborative Care Agreements Soft Contract between primary care and nephrologist Defines responsibilities of primary care Provide pertinent clinical information to inform the consultation prior to the scheduled visit. Initiate a phone call if the condition is emergent Provide timely referrals with adequate number of visits to treat the condition. Defines responsibilities of nephrologist Timely communication of consultation (7 days routine & 48 hours emergent) – fax if no electronic information sharing No consultation to other specialist initiated without primary care input
Slide 34-

Kidneydamage and normal or  GFR Kidneydamage and mild  GFR Severe GFR Kidneyfailure Moderate  GFR Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Nephrologist Primary Care Practitioner The Patient (always) and other subspecialists (as needed) GFR 90 60 30 15 Who Should be Involved in the Patient Safety Approach to CKD? Patient safety Consult?
Slide 35-

Impact of primary care CKD detection with a patient safety approach Fink et al. Am J Kidney Dis. 2009,53:681-668 Patient Safety Following CKD detection Improved diagnosis creates opportunity for strategic preservation of kidney function
Slide 36-

CKD Patient Safety Issues Medication errors Toxicity (nephrologic or other) Improper dosing Inadequate monitoring Electrolytes Hyperkalemia Hypoglycemia Hypermagnesemia Hyperphosphatemia Miscellaneous Multidrug-resistant infections Vessel preservation/dialysis access Fink JC, Brown J, Hsu, VD, et al. Am J Kidney Dis 2009;53:681-668.
Slide 37-

CKD Patient Safety Issues Diagnostic tests Iodinated contrast media: AKI Gadolinium-based contrast: NSF Sodium Phosphate bowel preparations: AKI, CKD CVD Missed diagnosis Improper management Fluid management Hypotension AKI CHF exacerbation AKI = acute kidney injury; CHF = congestive heart failure; NSF = nephrogenic systemic fibrosis. Fink JC, Brown J, Hsu, VD, et al. Am J Kidney Dis 2009;53:681-668..
Slide 38-

Common Medications Requiring DoseReduction in CKD Allopurinol Gabapentin CKD 4- Max dose 300mg qd CKD 5- Max dose 300mg qod Reglan Reduce 50% for eGFR< 40 Can cause irreversible EPS with chronic use Narcotics Methadone and fentanyl best for ESRD patients Lowest risk of toxic metabolites Renally cleared beta blockers Atenolol, bisoprolol, nadolol Digoxin Some Statins Lovastatin, pravastatin, simvastatin. Fluvastatin, rosuvastatin Antimicrobials Antifungals, aminoglycosides, Bactrim, Macrobid Enoxaparin Methotrexate Colchicine
Slide 39-

Key Points on Medications in CKD CKD patients at high risk for drug-related adverse events Several classes of drugs renally eliminated Consider kidney function and current eGFR (not just SCr) when prescribing meds Minimize pill burden as much as possible Remind CKD patients to avoid NSAIDs No Dual RAAS blockade Any med with >30% renal clearance probably needs dose adjustment for CKD No bisphosphonates for eGFR <30 Avoid GAD for eGFR <30
Slide 40-

*Significant albuminuria is defined as ACR ≥300 mg/g (≥30 mg/mmol) or AER ≥300 mg/24 hours, approximately equivalent to PCR ≥500 mg/g (≥50 mg/mmol) or PER ≥500 mg/24 hours **Progression of CKD is defined as one or more of the following: 1) A decline in GFR category accompanied by a 25% or greater drop in eGFR from baseline; and/or 2) rapid progression of CKD defined as a sustained decline in eGFR of more than 5ml/min/1.73m2/year. KDOQI US Commentary on the 2012 KDIGO Evaluation and Management of CKD Indications for Referral to Specialist Kidney Care Services for People with CKD Acute kidney injury or abrupt sustained fall in GFR GFR <30 ml/min/1.73m2 (GFR categories G4-G5) Persistent albuminuria (ACR > 300 mg/g)* Atypical Progression of CKD** Urinary red cell casts, RBC more than 20 per HPF sustained and not readily explained Hypertension refractory to treatment with 4 or more antihypertensive agents Persistent abnormalities of serum potassium Recurrent or extensive nephrolithiasis Hereditary kidney disease
Slide 41-

Observational Studies of Early vs. Late Nephrology Consultation Chan M, et al. Am J Med. 2007;120:1063-1070. http://download.journals.elsevierhealth.com/pdfs/journals/0002-9343/PIIS000293430700664X.pdf KDIGO CKD Work Group. Kidney Int Suppls. 2013;3:1-150.
Slide 42-

Take Home Points PCPs play an important role Identify risk factors Know patient’s GFR using appropriate screening tools Help your patient adjust medication Modify diet Partner and refer to specialist
Slide 43-

Additional Online Resources for CKD Learning National Kidney Foundation: www.kidney.org United States Renal Data Service: www.usrds.org CDC’s CKD Surveillance Project: http://nccd.cdc.gov/ckd National Kidney Disease Education Program (NKDEP): http://nkdep.nih.gov